144 related articles for article (PubMed ID: 9987826)
1. Synthetic inhibitors of DNA topoisomerase I and II.
Katayama H; Kawada Y; Kaneko K; Oshiyama T; Takatsu N
Chem Pharm Bull (Tokyo); 1999 Jan; 47(1):48-53. PubMed ID: 9987826
[TBL] [Abstract][Full Text] [Related]
2. F 11782, a dual inhibitor of topoisomerases I and II with an original mechanism of action in vitro, and markedly superior in vivo antitumour activity, relative to three other dual topoisomerase inhibitors, intoplicin, aclarubicin and TAS-103.
Etiévant C; Kruczynski A; Barret JM; Perrin D; van Hille B; Guminski Y; Hill BT
Cancer Chemother Pharmacol; 2000; 46(2):101-13. PubMed ID: 10972479
[TBL] [Abstract][Full Text] [Related]
3. Dicationic bis(9-methylphenazine-1-carboxamides): relationships between biological activity and linker chain structure for a series of potent topoisomerase targeted anticancer drugs.
Gamage SA; Spicer JA; Finlay GJ; Stewart AJ; Charlton P; Baguley BC; Denny WA
J Med Chem; 2001 Apr; 44(9):1407-15. PubMed ID: 11311063
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and cytotoxicity of indolopyrrolemaleimides.
Xu GQ; Guo P; Zhang C; He QJ; Yang B; Hu YZ
Chem Pharm Bull (Tokyo); 2007 Sep; 55(9):1302-7. PubMed ID: 17827752
[TBL] [Abstract][Full Text] [Related]
5. Lamellarin D: a novel potent inhibitor of topoisomerase I.
Facompré M; Tardy C; Bal-Mahieu C; Colson P; Perez C; Manzanares I; Cuevas C; Bailly C
Cancer Res; 2003 Nov; 63(21):7392-9. PubMed ID: 14612538
[TBL] [Abstract][Full Text] [Related]
6. Novel angular benzophenazines: dual topoisomerase I and topoisomerase II inhibitors as potential anticancer agents.
Vicker N; Burgess L; Chuckowree IS; Dodd R; Folkes AJ; Hardick DJ; Hancox TC; Miller W; Milton J; Sohal S; Wang S; Wren SP; Charlton PA; Dangerfield W; Liddle C; Mistry P; Stewart AJ; Denny WA
J Med Chem; 2002 Jan; 45(3):721-39. PubMed ID: 11806724
[TBL] [Abstract][Full Text] [Related]
7. Semi-synthesis, topoisomerase I and kinases inhibitory properties, and antiproliferative activities of new rebeccamycin derivatives.
Moreau P; Gaillard N; Marminon C; Anizon F; Dias N; Baldeyrou B; Bailly C; Pierré A; Hickman J; Pfeiffer B; Renard P; Prudhomme M
Bioorg Med Chem; 2003 Nov; 11(23):4871-9. PubMed ID: 14604648
[TBL] [Abstract][Full Text] [Related]
8. Antitumor agents. I. DNA topoisomerase II inhibitory activity and the structural relationship of podophyllotoxin derivatives as antitumor agents.
Terada T; Fujimoto K; Nomura M; Yamashita J; Kobunai T; Takeda S; Wierzba K; Yamada Y; Yamaguchi H
Chem Pharm Bull (Tokyo); 1992 Oct; 40(10):2720-7. PubMed ID: 1334447
[TBL] [Abstract][Full Text] [Related]
9. Synthesis, topoisomerase I inhibitory activity and in vitro cytotoxicity of camptothecin derivatives bearing five-membered heterocycle containing 10-substituents.
Zhao R; Guan LL; Oreski B; Lown JW
Anticancer Drug Des; 1998 Mar; 13(2):145-57. PubMed ID: 9524556
[TBL] [Abstract][Full Text] [Related]
10. Ring-substituted 11-oxo-11H-indeno[1,2-b]quinoline-6-carboxamides with similar patterns of cytotoxicity to the dual topo I/II inhibitor DACA.
Deady LW; Desneves J; Kaye AJ; Thompson M; Finlay GJ; Baguley BC; Denny WA
Bioorg Med Chem; 1999 Dec; 7(12):2801-9. PubMed ID: 10658584
[TBL] [Abstract][Full Text] [Related]
11. Synthesis of 2-(thienyl-2-yl or -3-yl)-4-furyl-6-aryl pyridine derivatives and evaluation of their topoisomerase I and II inhibitory activity, cytotoxicity, and structure-activity relationship.
Thapa P; Karki R; Choi H; Choi JH; Yun M; Jeong BS; Jung MJ; Nam JM; Na Y; Cho WJ; Kwon Y; Lee ES
Bioorg Med Chem; 2010 Mar; 18(6):2245-2254. PubMed ID: 20188578
[TBL] [Abstract][Full Text] [Related]
12. Syntheses of novel antitumor dihydroxanthone derivatives with inhibitory activity against DNA topoisomerase II.
Sato S; Suga Y; Yoshimura T; Nakagawa R; Tsuji T; Umemura K; Andoh T
Bioorg Med Chem Lett; 1999 Sep; 9(18):2653-6. PubMed ID: 10509910
[TBL] [Abstract][Full Text] [Related]
13. Homocamptothecin, an E-ring-modified camptothecin analogue, generates new topoisomerase I-mediated DNA breaks.
Bailly C; Lansiaux A; Dassonneville L; Demarquay D; Coulomb H; Huchet M; Lavergne O; Bigg DC
Biochemistry; 1999 Nov; 38(47):15556-63. PubMed ID: 10569939
[TBL] [Abstract][Full Text] [Related]
14. Bisindolylmaleimides linked to DNA minor groove binding lexitropsins: synthesis, inhibitory activity against topoisomerase I, and biological evaluation.
Xie G; Gupta R; Atchison K; Lown JW
J Med Chem; 1996 Mar; 39(5):1049-55. PubMed ID: 8676340
[TBL] [Abstract][Full Text] [Related]
15. Novel antitumor indolizino[6,7-b]indoles with multiple modes of action: DNA cross-linking and topoisomerase I and II inhibition.
Chaniyara R; Tala S; Chen CW; Zang X; Kakadiya R; Lin LF; Chen CH; Chien SI; Chou TC; Tsai TH; Lee TC; Shah A; Su TL
J Med Chem; 2013 Feb; 56(4):1544-63. PubMed ID: 23360284
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and evaluation of novel pyrimido-acridone, -phenoxadine, and -carbazole as topoisomerase II inhibitors.
Kamata J; Okada T; Kotake Y; Niijima J; Nakamura K; Uenaka T; Yamaguchi A; Tsukahara K; Nagasu T; Koyanagi N; Kitoh K; Yoshimatsu K; Yoshino H; Sugumi H
Chem Pharm Bull (Tokyo); 2004 Sep; 52(9):1071-81. PubMed ID: 15340192
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and antitumor activity of 4-aminomethylthioxanthenone and 5-aminomethylbenzothiopyranoindazole derivatives.
Perni RB; Wentland MP; Huang JI; Powles RG; Aldous S; Klingbeil KM; Peverly AD; Robinson RG; Corbett TH; Jones JL; Mattes KC; Rake JB; Coughlin SA
J Med Chem; 1998 Sep; 41(19):3645-54. PubMed ID: 9733489
[TBL] [Abstract][Full Text] [Related]
18. Antitumor quinolones with mammalian topoisomerase II mediated DNA cleavage activity.
Yamashita Y; Ashizawa T; Morimoto M; Hosomi J; Nakano H
Cancer Res; 1992 May; 52(10):2818-22. PubMed ID: 1316228
[TBL] [Abstract][Full Text] [Related]
19. Nonproductive rearrangement of DNA topoisomerase I and II genes: correlation with resistance to topoisomerase inhibitors.
Tan KB; Mattern MR; Eng WK; McCabe FL; Johnson RK
J Natl Cancer Inst; 1989 Nov; 81(22):1732-5. PubMed ID: 2553992
[TBL] [Abstract][Full Text] [Related]
20. Lamellarin D: a novel pro-apoptotic agent from marine origin insensitive to P-glycoprotein-mediated drug efflux.
Vanhuyse M; Kluza J; Tardy C; Otero G; Cuevas C; Bailly C; Lansiaux A
Cancer Lett; 2005 Apr; 221(2):165-75. PubMed ID: 15808402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
